Tempus AI, Inc., a leader in artificial intelligence and precision medicine, announced the launch of a new program specifically geared towards using algorithms to surface patients who are more likely to test positive for actionable biomarkers, and who should receive confirmatory testing in accordance with clinical guidelines. This program is part of the larger Tempus Next platform, which is designed to identify care gaps and equip clinicians with actionable insights at the point of care. The new Next program is now available and initially focused on the identification of care gaps associated with the human epidermal growth factor receptor 2 (HER2) testing recommended under clinical guidelines for patients with select metastatic cancers.
As part of the initial launch, Tempus has built an algorithm that runs as part of xR, the company’s RNA sequencing assay, to help surface patients who are particularly likely to benefit from on-guideline immunohistochemistry (IHC) testing. The algorithm, which is run as part of Tempus’ xR CAP/CLIA Laboratory Developed Test, uses RNA data to predict IHC/ISH positivity in a tumor sample.
Also Read: Vaniam Group™ Accelerates Innovation With Appointment of Industry Leader Steve Tulk as Chief Technology Officer
Tempus is initially deploying the program at a set of pilot sites. Tempus will notify physicians of patients who are identified by the algorithm as more likely to be HER2 positive, so that they can consider ordering confirmatory IHC testing from their laboratory of choice. The development of this program was funded by Tempus and one or more life sciences company sponsors.
“This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep connectivity with providers, comprehensive testing portfolio, and AI-enabled data analytics to deliver a tool that physicians can use in real-time to provide patients with the most up-to-date, guideline-directed care,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “Next demonstrates how the practical application of AI can have a positive impact on everyday clinical care by meeting the needs of patients as treatment choices become increasingly complex.”
Source: Businesswire
